Evidence map›Paper›PMID 32298807›Full record

ReviewBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2020

Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic.

Veronika Bachanova, Michael R Bishop, Parastoo Dahi, Bhagirathbhai Dholaria, Stephan A Grupp, Brandon Hayes-Lattin, Murali Janakiram, Richard T Maziarz, Joseph P McGuirk, Loretta J Nastoupil and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Guideline
  2. Guideline
  3. Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020
    Guideline
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. COVID-19 in patients with cancer: Risks and precautions.The American journal of emergency medicine · 2021
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Veronika BachanovaDivision of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN.
Michael R BishopHematopoietic Cellular Therapy Program, Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL.
Parastoo DahiAdult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York, NY.
Bhagirathbhai DholariaDivision of Hematology Oncology, Department of Medicine, Vanderbilt School of Medicine, Nashville, TN.
Stephan A GruppSection of Cellular Therapy and Transplant, Children's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
Brandon Hayes-LattinKnight Cancer Institute, Oregon Health & Science University, Portland, OR.
Murali JanakiramDivision of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN.
Richard T MaziarzKnight Cancer Institute, Oregon Health & Science University, Portland, OR.
Joseph P McGuirkDivision of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS.
Loretta J NastoupilDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Olalekan O OluwoleDivision of Hematology Oncology, Department of Medicine, Vanderbilt School of Medicine, Nashville, TN.
Miguel-Angel PeralesAdult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York, NY.
David L PorterUniversity of Pennsylvania and Abramson Cancer Center, Philadelphia, PA. Electronic address: david.porter@pennmedicine.upenn.edu.
Peter A RiedellHematopoietic Cellular Therapy Program, Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL. Electronic address: priedell@medicine.bsd.uchicago.edu.
CAR T-cell Consortium

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Elisa de Stanchina · 1985 to 2026
$347.4M
Project 3: Combinatorial and gene-editing approaches to enhance the efficacy of CAR T cell therapy of multiple myeloma.P01CA214278 · NCI · UNIVERSITY OF PENNSYLVANIA · PI CARL H. JUNE · 2017 to 2026
$26.8M
NCI NIH HHS P01 CA214278NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

The SARS-CoV-2 coronavirus (COVID-19) pandemic has significantly impacted the delivery of cellular therapeutics, including chimeric antigen receptor (CAR) T cells. This impact has extended beyond patient care to include logistics, administration, and distribution of increasingly limited health care resources. Based on the collective experience of the CAR T-cell Consortium investigators, we review and address several questions and concerns regarding cellular therapy administration in the setting of COVID-19 and make general recommendations to address these issues. Specifically, we address (1) necessary resources for safe administration of cell therapies; (2) determinants of cell therapy utilization; (3) selection among patients with B cell non-Hodgkin lymphomas and B cell acute lymphoblastic leukemia; (4) supportive measures during cell therapy administration; (5) use and prioritization of tocilizumab; and (6) collaborative care with referring physicians. These recommendations were carefully formulated with the understanding that resource allocation is of the utmost importance, and that the decision to proceed with CAR T cell therapy will require extensive discussion of potential risks and benefits. Although these recommendations are fluid, at this time it is our opinion that the COVID-19 pandemic should not serve as reason to defer CAR T cell therapy for patients truly in need of a potentially curative therapy.

Indexed as

PandemicsAntibodies, Monoclonal, HumanizedCommunicable Disease ControlCoronavirus InfectionsCOVID-19Health Care RationingHumansImmunotherapy, AdoptiveLymphoma, B-CellPneumonia, ViralPractice Guidelines as TopicPrecursor B-Cell Lymphoblastic Leukemia-LymphomaReceptors, Antigen, T-CellReceptors, Chimeric AntigenTissue DonorsT-LymphocytesAntibodies, Monoclonal, HumanizedReceptors, Antigen, T-CellReceptors, Chimeric AntigentocilizumabCellular therapyChimeric antigen receptor T cellsCoronavirusCOVID-19Pandemic

Identifiers

PMID32298807
PMCPMC7194685

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.